Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:53
|
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
  • [1] Immunohistochemical Detection of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor in Canine Vascular Endothelial Tumours
    Anwar, Sh.
    Yanai, T.
    Sakai, H.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2015, 153 (04) : 278 - 282
  • [2] Activation of the Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor System in Periodontitis: A Case-Control Study
    Khudhur, Ahmed
    Dowson, Christopher
    Bissett, Susan M.
    van de Merwe, Rachel
    Taylor, John J.
    Preshaw, Philip M.
    Jaedicke, Katrin M.
    INTERNATIONAL JOURNAL OF DENTAL HYGIENE, 2024,
  • [3] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [4] Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors
    Gutova, Margarita
    Najbauer, Joseph
    Frank, Richard T.
    Kendall, Stephen Edward
    Gevorgyan, Anna
    Metz, Marianne Z.
    Guevorkian, Mark
    Edmiston, Marissa
    Zhao, Donghong
    Glackin, Carlotta A.
    Kim, Seung U.
    Aboody, Karen S.
    STEM CELLS, 2008, 26 (06) : 1406 - 1413
  • [5] Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients
    Wang, Li
    Madigan, Michele C.
    Chen, Hongmin
    Liu, FengHua
    Patterson, Kate I.
    Beretov, Julia
    O'Brien, Philippa M.
    Li, Yong
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 265 - 272
  • [6] Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients
    Levicar, N
    Kos, J
    Blejec, A
    Golouh, R
    Vrhovec, I
    Frkovic-Grazio, S
    Lah, TT
    CANCER DETECTION AND PREVENTION, 2002, 26 (01): : 42 - 49
  • [7] Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers
    Herszenyi, Laszlo
    Istvan, Gabor
    Cardin, Romilda
    De Paoli, Massimo
    Plebani, Mario
    Tulassay, Zsolt
    Farinati, Fabio
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2008, 17 (05) : 438 - 445
  • [8] Targeting urokinase-type plasminogen activator and its receptor for cancer therapy
    Nozaki, Shinichi
    Endo, Yoshio
    Nakahara, Hirokazu
    Yoshizawa, Kunio
    Ohara, Teruhisa
    Yamamoto, Etsuhide
    ANTI-CANCER DRUGS, 2006, 17 (10) : 1109 - 1117
  • [9] The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer
    Mazar, AP
    ANTI-CANCER DRUGS, 2001, 12 (05) : 387 - 400
  • [10] In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression
    Rasouli, Bahareh Sadat
    Ghadimi-Darsajini, Ali
    Nekouian, Reza
    Iragian, Gholam-Reza
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2017, 13 (02) : 246 - 251